Program
inclisiran
Also written as “Inclisiran”, “Inclisiran Sodium” and “ALN-PCSSC”.
Its studies are mostly in Hypercholesterolemia · Atherosclerosis · Homozygous Familial Hypercholesterolemia · Acute Coronary Syndrome · Hyperlipoproteinemia Type II, led by 2 companies.
Drug pageInclisiran: every studyAll 51 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartisits history only | 3615 open or running | phase 4since Dec 13, 2021 | Nov 3, 2015 | Nov 27, 2026phase 4 · NCT06501443 |
| Alnylam Pharmaceuticalsits history only | 10 open or running | phase 1since Dec 5, 2014 | Dec 5, 2014 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 20 earlier studies, Dec 5, 2014 to Dec 13, 2021.
- Dec 9, 2015Named inclisiranINNProposed as its International Nonproprietary Name in WHO's List 114
- Apr 29, 2022Phase 3 study in Coronary Artery DiseaseNovartis · NCT05360446 · 610 enrolled · United States, Argentina, Australia and more
- Dec 27, 2022Phase 3 study in Homozygous Familial HypercholesterolemiaNovartis · NCT05682378 · 195 planned · United States, Argentina, Brazil and more
- Feb 13, 20232 phase 3 studiesNovartis · NCT05739383, NCT05763875
- May 24, 2023Phase 3 study in AtherosclerosisNovartis · NCT05888103 · 207 enrolled · China
- Apr 15, 20243 phase 4 studiesNovartis · NCT06372925, NCT06386419, NCT06431763
- Jun 21, 2024Phase 4 study in HypercholesterolemiaNovartis · NCT06501443 · 520 planned · Argentina, Brazil
- Sep 11, 20242 phase 3 studiesNovartis · NCT06597019, NCT06597006
- Feb 3, 2025Phase 3 study in AtherosclerosisNovartis · NCT06813911 · 246 enrolled · United States, China, France and more
- Mar 6, 2025Phase 4 study in Coronary DiseaseNovartis · NCT06941792 · 1,590 enrolled · China
- Jul 31, 2025Phase 3 study in Acute Coronary SyndromeNovartis · NCT07102628 · 305 enrolled · Australia, Canada, China and more
- May 20, 2026Phase 2 study in HypercholesterolemiaNovartis · NCT07610278 · 120 planned · United States
- May 29, 2026Phase 1 study in Inclisiran FormulationNovartis · NCT07626281 · 152 planned · United States
- Jun 29, 2026Phase 4 study in Acute Coronary SyndromeNovartis · NCT07684469 · 300 planned
- Oct 30, 2026Primary completion moved from 2027-02-28 to 2028-02-29Date moved laterphase 4 · +12 months · NCT07684469
Ahead
- Nov 27, 2026Primary completion: phase 4 study in HypercholesterolemiaNovartis · NCT06501443
- Dec 21, 2026Primary completion: phase 1 study in Inclisiran FormulationNovartis · NCT07626281
- Dec 30, 2026Primary completion: phase 4 study in Plaque, AtheroscleroticNovartis · NCT06372925
- Jan 16, 2027Primary completion: phase 3 study in Acute Coronary SyndromeNovartis · NCT07102628
TargetBeta
“The present clinical trial adopted inclisiran, a PCSK9 inhibitor with well-documented clinical safety and robust lipid-lowering effects, in combination with amlodipine besylate.”study text, by rule · the study
Other programs on PCSK9
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| alirocumabrule | Sanofi | phase 4 | 48 |
| evolocumabrule | Amgen | phase 4 | 45 |
| lerodalcibeprule | lib-therapeutics-llc | phase 3 | 14 |
| tafolecimabrule | Innovent Biologics | phase 3 | 8 |
| recaticimabrule | Jiangsu HengRui Medicine | phase 3 | 7 |
| QLC7401rule | Qilu Pharmaceutical | phase 3 | 5 |
| SYH2053rule | CSPC Pharmaceutical Group | phase 3 | 5 |
| SAL003rule | Shenzhen Salubris Pharmaceuticals | phase 3 | 3 |
| VERVE-102 | Eli Lilly | phase 2 | 2 |
| DNV001rule | hangzhou-dinovate-biotech-co-ltd | phase 2 | 1 |
| RBD7022rule | Qilu Pharmaceutical | phase 1 | 2 |
Studies
All 37 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07684469Acute Coronary Syndrome | 4 | Not yet recruiting | Novartis | Feb 29, 2028 | 300 |
| NCT07626281Inclisiran Formulation · United States | 1 | Recruiting | Novartis | Dec 21, 2026 | 152 |
| NCT07610278Hypercholesterolemia · United States | 2 | Recruiting | Novartis | Apr 28, 2027 | 120 |
| NCT07102628Acute Coronary Syndrome · Australia, Canada, China and more | 3 | Active, not recruiting | Novartis | Jan 16, 2027 | 305 |
| NCT06941792Coronary Disease · China | 4 | Active, not recruiting | Novartis | Apr 30, 2027 | 1,590 |
| NCT06813911Atherosclerosis · United States, China, France and more | 3 | Active, not recruiting | Novartis | Feb 3, 2028 | 246 |
| NCT06597019Hyperlipoproteinemia Type II · United States, Argentina, Austria and more | 3 | Recruiting | Novartis | Mar 21, 2028 | 60 |
| NCT06597006Homozygous Familial Hypercholesterolemia · United States, Austria, China and more | 3 | Recruiting | Novartis | Mar 21, 2028 | 9 |
| NCT06501443Hypercholesterolemia · Argentina, Brazil | 4 | Recruiting | Novartis | Nov 27, 2026 | 520 |
| NCT06431763Hypercholesterolemia · Germany | 4 | Completed | Novartis | Dec 1, 2025 | 402 |
| NCT06386419Primary Hypercholesterolemia · India | 4 | Completed | Novartis | Jan 13, 2026 | 65 |
| NCT06372925Plaque, Atherosclerotic · China | 4 | Active, not recruiting | Novartis | Dec 30, 2026 | 318 |
| NCT05888103Atherosclerosis · China | 3 | Completed | Novartis | Apr 2, 2024 | 207 |
| NCT05763875Hypercholesterolemia · United States, Colombia, Germany and more | 3 | Completed | Novartis | Jun 20, 2024 | 350 |
| NCT05739383Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | Apr 16, 2029 | 14,012 |
| NCT05682378Homozygous Familial Hypercholesterolemia · United States, Argentina, Brazil and more | 3 | Recruiting | Novartis | Mar 25, 2032 | 195 |
| NCT05360446Coronary Artery Disease · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | Oct 26, 2026 | 610 |
| NCT05192941Hypercholesterolemia · Bulgaria, Czechia, Estonia and more | 4 | Completed | Novartis | Jun 11, 2024 | 1,770 |
| NCT05030428Atherosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Novartis | May 10, 2027 | 17,004 |
| NCT04929249Atherosclerosis · United States | 3 | Completed | Novartis | Sep 15, 2023 | 450 |
| NCT04873934Acute Coronary Syndrome · United States | 3 | Completed | Novartis | Aug 7, 2024 | 400 |
| NCT04807400Atherosclerosis · United Kingdom | 3 | Completed | Novartis | Jan 13, 2023 | 892 |
| NCT04774003Hyperlipidemias · China | 1 | Completed | Novartis | Oct 18, 2021 | 40 |
| NCT04765657Hypercholesterolemia · China, Singapore, South Korea and more | 3 | Active, not recruiting | Novartis | Jun 9, 2022 | 345 |
| NCT04666298Hypercholesterolemia · Japan | 2 | Completed | Novartis | Apr 18, 2022 | 312 |
| NCT04659863Homozygous Familial Hypercholesterolemia · United States, Canada, France and more | 3 | Completed | Novartis | Oct 30, 2023 | 13 |
| NCT04652726Familial Hypercholesterolemia - Heterozygous · United States, Argentina, Brazil and more | 3 | Completed | Novartis | Nov 9, 2023 | 141 |
| NCT03851705Homozygous Familial Hypercholesterolemia · Hong Kong, Israel, Russian Federation and more | 3 | Completed | Novartis | Mar 2, 2020 | 56 |
| NCT03814187Hypercholesterolemia · United States, Canada, Czechia and more | 3 | Completed | Novartis | Feb 13, 2023 | 3,275 |
| NCT03400800Hypercholesterolemia · Czechia, Germany, Hungary and more | 3 | Completed | Novartis | Jul 31, 2019 | 1,617 |
| NCT03399370Hypercholesterolemia · United States | 3 | Completed | Novartis | Sep 10, 2019 | 1,561 |
| NCT03397121Hypercholesterolemia · United States, Canada, Czechia and more | 3 | Completed | Novartis | Aug 27, 2019 | 482 |
| NCT03159416Renal Insufficiency · New Zealand | 1 | Completed | Novartis | Mar 24, 2018 | 31 |
| NCT03060577Atherosclerosis · United States, Canada, Germany and more | 2 | Completed | Novartis | Dec 17, 2021 | 382 |
| NCT02963311Homozygous Familial Hypercholesterolemia · United States, Netherlands, South Africa | 2 | Completed | Novartis | Oct 8, 2018 | 9 |
| NCT02597127Atherosclerosis · United States, Canada, Germany and more | 2 | Completed | Novartis | Jun 7, 2017 | 501 |
| NCT02314442Hypercholesterolemia · United Kingdom | 1 | Completed | Alnylam Pharmaceuticals | May 2015 | 70 |
How it is read
Names in the registry
- “Inclisiran”, 16 entries
- “Inclisiran Sodium”, 4 entries
- “inclisiran”, 3 entries
- “ALN-PCSSC”, 3 entries
- “Inclisiran sodium 300 mg”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 13 studies
- Atherosclerosis, 7 studies
- Homozygous Familial Hypercholesterolemia, 5 studies
- Acute Coronary Syndrome, 3 studies
- Hyperlipoproteinemia Type II, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.